The hedge fund guru’s Q2 moves added ECYT gains to his pocket while saving him greater losses in VRX.
A glimpse into why Louise Chen believes Valeant is the better biotech play than Teva down the line.
James “Jim” Flynn first walked onto the Deerfield Management team seventeen years ago, since a firm that cares about strides in the healthcare …
Valeant Pharmaceuticals Intl Inc (NYSE:VRX) routinely evaluates refinancing opportunities, including capital markets transactions, to continue to enhance its capital structure. As part of this, the …
A first glance at this hedge fund’s strategic Q2 moves in biotech sector.
CFO Paul Herendeen sought out to convince investors to put their money into the long game.
Has this billion-dollar fund made the right call on ARRY, VRX, and HIMX?
Three key biopharma trades from the highly-successful $78 billion Renaissance fund
Ortho Dermatologics, a division of Valeant Pharmaceuticals Intl Inc (NYSE:VRX) announced it has submitted a New Drug Application (NDA) to the FDA for IDP-118 (halobetasol propionate …
Irina Rivkind Koffler Doubles Down on Bearish Bet
